Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
|Articles|October 22, 2012
Both Parties See Gains Coming From Medicare Debate
Advertisement
A little more than two weeks before Election Day, Republicans and Democrats alike say Medicare is working to their political advantage in campaigns for the White House and Congress.
They can't both be right, and no matter which side is, this is one campaign clash with consequences extending well beyond Nov. 6.
Read the full story:
Source: The Associated Press
Advertisement
Related to this article
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.
Follitropin delta yields cumulative ongoing pregnancy in 64.0% of patients under 35 and 43.9% of those 35 to 42 in 2 placebo-controlled IVF trials.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
3
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
4
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
5